On July 9, 2026, FDA approved isatuximab-irfc (Sarclisa Escena, Sanofi Aventis) for subcutaneous injection in multiple myeloma, extending to all currently approved IV isatuximab indications: In ...
Who Owns the Message? Key Takeaways from OncoDaily’s Exclusive Brunch at ESMO 2026 ...
OncoDaily Grand Rounds at ESMO 2026: Key Discussions and Clinical Perspectives on Bladder Cancer, Part 1 ...
Who Owns the Message? Key Takeaways from OncoDaily’s Exclusive Brunch at ESMO 2026 ...
COCOON shows lazertinib lead-in plus simplified prophylaxis reduced grade ≥2 skin toxicity to 18% with SC amivantamab in EGFR ...
At the Community Oncology Global Congress (COGC 2026), organized by OncoDaily, Amol Akhade, Senior Consultant in Medical ...
CROWN ctDNA data link early lorlatinib progression to genomic complexity, TP53 and bypass pathways rather than new ALK ...
OptiTROP-Lung04 (NCT05870319), a pivotal phase 3 trial presented by Prof. Li Zhang (Guangzhou, China) at the ESMO Congress 2025, evaluated the efficacy and safety of the novel TROP2-directed ...
VIKTORIA-1 shows gedatolisib maintained strong PFS benefit over alpelisib in PIK3CA-mutant HR+/HER2− breast cancer, including ...
SHR-A2102 at ESMO 2026 Shows 47.2% Response Rate in Recurrent or Metastatic Cervical Cancer / cancer, ESMO, esmo 2026, ...
MONARCH shows median OS of 32.1 vs 24.6 months with abemaciclib after prior CDK4/6 therapy, but the survival difference was ...
HBI-8000-303 evaluates the HDAC inhibitor HBI-8000 plus nivolumab in advanced melanoma, examining PFS, response, safety, and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results